Brought to you by 
Kiniksa raises $200mm through Series C
25 May 2018
Executive Summary
Kiniksa Pharmaceuticals Ltd. (autoinflammatory and autoimmune disease therapies) raised $200mm in its Series C round. Returning backers Baker Brothers and ArrowMark participated, and were joined by new investors Cormorant, Deerfield, Fidelity Funds, Sofinnova Venture Partners, and Venrock Funds. Entities affiliated with Dr. Robert Desnick also took part, along with company officers and directors.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kiniksa raises $200mm through Series C
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice